Skip to main content
ALLO
NASDAQ Life Sciences

Allogene 将其关键的ALPHA3癌症试验扩展至韩国和澳大利亚

feedReported by GlobeNewswire
Sentiment info
Positive
Importance info
7
Price
$2.46
Mkt Cap
$801.693M
52W Low
$0.862
52W High
$4.46
Market data snapshot near publication time

summarizeSummary

Allogene Therapeutics宣布将其针对首线大B细胞淋巴瘤的cema-cel的关键性2期ALPHA3试验扩展至韩国和澳大利亚，从而将全球试验地点从60多个增加到80多个。这一战略性扩展是在4月13日宣布的极为积极的中期无效性分析结果之后进行的，这些结果表明了58.3%的最小残留疾病清除率。这种扩展预计将加速cema-cel的招募和全球开发，利用这些新地区已建立的临床研究基础设施。这是一个积极的运营步骤，表明了强有力的进展和对推进关键管道资产向潜在的生物制剂许可申请提交的承诺。投资者将监测招募进展以及预计于2027年中期进行的中期无事件生存分析。

在该公告发布时，ALLO的交易价格为$2.46，交易所为NASDAQ，所属行业为Life Sciences，市值约为$8亿。 52周交易区间为$0.86至$4.46。 这则新闻被评估为积极市场情绪，重要性评分为7/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed ALLO - Latest Insights

ALLO
Apr 21, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Allogene Expands Pivotal ALPHA3 Cancer Trial to South Korea and Australia
Sentiment: Positive
View Wiseek Article
ALLO
Apr 20, 2026, 5:21 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Allogene Therapeutics Seeks Shareholder Approval to Double Authorized Common Stock to 800 Million Shares
Sentiment: Neutral
View Wiseek Article
ALLO
Apr 16, 2026, 4:45 PM EDT
Source: Reuters
Importance Score:
8
Allogene Therapeutics Closes $200.4 Million Public Offering, Securing Capital
Sentiment: Neutral
View Wiseek Article
ALLO
Apr 15, 2026, 4:35 PM EDT
Filing Type: 8-K
Importance Score:
8
Allogene Therapeutics Prices $175M Public Offering at $2.00/Share Following Positive Trial Results
Sentiment: Negative
View Wiseek Article
ALLO
Apr 15, 2026, 4:33 PM EDT
Filing Type: 424B5
Importance Score:
8
Allogene Therapeutics Prices $175M Public Offering Following Positive Clinical Trial Results
Sentiment: Neutral
View Wiseek Article
ALLO
Apr 13, 2026, 4:09 PM EDT
Filing Type: 8-K
Importance Score:
8
Allogene Therapeutics Announces Proposed Public Offering Following Positive Trial Results
Sentiment: Neutral
View Wiseek Article
ALLO
Apr 13, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
8
Allogene Therapeutics Proposes $175 Million Public Offering of Common Stock
Sentiment: Negative
View Wiseek Article
ALLO
Apr 13, 2026, 7:45 AM EDT
Filing Type: 8-K
Importance Score:
9
Allogene Reports Highly Positive Interim Futility Analysis for Pivotal Phase 2 ALPHA3 Trial of Cema-cel in LBCL
Sentiment: Positive
View Wiseek Article
ALLO
Apr 13, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
9
Pivotal ALPHA3 Trial Shows Cema-Cel Achieves 58.3% MRD Clearance, Significantly Outperforming Observation Arm
Sentiment: Positive
View Wiseek Article
ALLO
Mar 12, 2026, 4:15 PM EDT
Source: Wiseek News
Importance Score:
9
Allogene Therapeutics Extends Cash Runway to Q1 2028, Narrows 2025 Net Loss to $190.9M
Sentiment: Positive
View Wiseek Article